6 results
10-K
2023 FY
TSBX
Turnstone Biologics Corp
21 Mar 24
Annual report
8:51pm
to the same product if relevant criteria are met.
The FDA may also designate a product candidate as a regenerative medicine advanced therapy, or RMAT
424B4
TSBX
Turnstone Biologics Corp
21 Jul 23
Prospectus supplement with pricing info
7:14pm
if relevant criteria are met.
The FDA may also designate a product candidate as a regenerative medicine advanced therapy, or RMAT. The RMAT
S-1/A
TSBX
Turnstone Biologics Corp
23 Jun 23
IPO registration (amended)
9:49pm
as a regenerative medicine advanced therapy, or RMAT. The RMAT designation is intended to facilitate an efficient development program for, and expedited
S-1
TSBX
Turnstone Biologics Corp
12 Jun 23
IPO registration
4:28pm
be granted to the same product if relevant criteria are met.
The FDA may also designate a product candidate as a regenerative medicine advanced therapy
DRS
guy5zey
15 May 23
Draft registration statement
12:00am
- Prev
- 1
- Next